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Purpose: To determine if a circulating microRNA (miRNA) panel could be used to
distinguish between uveal melanoma and uveal nevi.
Methods: We report on a multicenter, cross-sectional study conducted between June
2012 and September 2015. The follow-up time was approximately 3 to 5 years. Blood
was drawn from participants presenting with a uveal nevus (n ¼ 10), localized uveal
melanoma (n ¼ 50), or metastatic uveal melanoma (n ¼ 5). Levels of 17 miRNAs were
measured in blood samples of study participants using a sensitive real-time PCR
system.
Results: A panel of six miRNAs (miR-16, miR-145, miR-146a, miR-204, miR-211, and
miR-363-3p) showed significant differences between participants with uveal nevi
compared with patients with localized and metastatic uveal melanoma. Importantly,
miR-211 was able to accurately distinguish metastatic disease from localized uveal
melanoma (P , 0.0001; area under the curve ¼ 0.96). When the six-miRNA panel was
evaluated as a group it had the ability to identify uveal melanoma when four or more
miRNAs (93% sensitivity and 100% specificity) reached or exceeded their cut-point.
Conclusions: This miRNA panel, in tandem with clinical findings, may be suited to
confirm benign lesions. In addition, due to the panel’s high precision in identifying
malignancy, it has the potential to augment melanoma detection in subsequent
clinical follow-up of lesions with atypical clinical features.
Translational Relevance: Uveal nevi mimic the appearance of uveal melanoma and
their transformation potential cannot be definitively determined without a biopsy.
This panel is most relevant at the nevus stage and in lesions with uncertain malignant
potential as a companion diagnostic tool to assist in clinical decision-making.
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Introduction
Melanoma of the uveal tract (iris, ciliary body, and
choroid) is the most common intraocular malignancy
in adults. Uveal melanoma (UM) can form in the iris,
located at the front of the eye, though most are
located in the posterior segment of the eye (ciliary
body or choroid), with the latter considered more
malignant. Due to their location, posterior UM are
often detected later and as such may be more prone to
metastasis, especially when carrying specific chromo-
somal aberrations (loss of chromosome 3 and gain of
chromosome 8q) determined cytogenetically follow-
ing intraocular biopsy.1 Several benign tumors (e.g.,
hemangiomas and uveal nevi) can mimic UM.
Importantly, all melanocytic nevi have the potential
to transform into melanoma, with the transformation
rate of choroidal nevi being higher than that of
cutaneous nevi (~1/200,000).2,3 It has been estimated
that progression of a choroidal nevus to UM occurs in
approximately 1 in 9000 cases.4 However, if high-risk
clinical features are identified, the risk for transfor-
mation is 69%.3 Therefore, close monitoring by an
ocular oncologist is required to detect the early signs
of malignancy.
Circulating biomarkers (proteins, cell-free DNA,
and microRNAs [miRNA]) have been intensely
studied in a wide range of malignancies as a minimally
invasive method of cancer detection and for predict-
ing prognosis. In UM, serum levels of DJ-1 (PARK7)
were found to be significantly associated with
choroidal nevus growth.5 Circulating GNAQ/GNA11
mutations (found in ~83% of UM6) have been
detected in plasma of metastatic UM patients7,8;
however, they are rarely detectable in patients with
localized disease.9 In recent years, circulating miRNA
has been found to be a highly sensitive and specific
method of identifying underlying malignancy in
cutaneous and UM.10–14
MiRNAs are short (~20–22 nt), noncoding RNAs
that are readily detectable in tissues and blood. We
previously identified a panel of melanoma-related
miRNAs that offered superior sensitivity to currently
used serologic markers for cutaneous melanoma
progression, recurrence, and survival.10 We therefore
sought to assess this panel in serum from patients with
choroidal nevi, localized UM, and metastatic UM.
We herein present a panel of circulating miRNA
that can accurately distinguish choroidal nevi from
localized UM, as well as detect metastatic disease with
high sensitivity and specificity.
Materials and Methods
Patient Specimen Details
A prospectively collected sample of patients was
ascertained at the Queensland Ocular Oncology
Service, Brisbane, Queensland, Australia and the
Lions Eye Institute and Royal Perth Hospital, Perth,
Western Australia, between June 2012 and September
2015. All patients gave written informed consent (in
accordance with the Declaration of Helsinki) under
approved protocols governed respectively by the
Human Research Ethics Committee of the QIMR
Berghofer Medical Research Institute (No. P1237),
Edith Cowan University (No. 11543), and Sir Charles
Gardner Hospital (No. 2013-246). All serum samples
were collected in 8.5-mL BD serum separator tubes
(SST; BD, North Ryde, Australia). Blood was left to
clot for 30 minutes at room temperature, then
centrifuged for 10 minutes at 1500 g. The serum
supernatant was then aliquoted into 1.5-mL cryovials
and stored at 808C until further use. Patient
demographics are given in Table 1.
Clinical Diagnostic Criteria
Each lesion was assessed using a combination of
fundoscopy, Optos widefield retinal imaging (Optos
Inc., Marlborough, MA), optical coherence tomogra-
phy, and B-scan ultrasonography. The diagnosis of
choroidal melanoma was based on the presence or
absence of features conferring high risk of growth in a
choroidal lesion.3 These features include lesion height
of more than 2 mm, visual symptoms (e.g., visual loss,
photopsia), low echogenicity on B-scan, the presence of
subretinal fluid and/or orange lipofuscin, close prox-
imity to the optic nerve (3 mm), and absence of
surrounding halo depigmentation or absence of
overlying retinal pigment epithelium (RPE) alterations
(e.g., drusen, atrophy, hyperplasia, detachment, fi-
brous metaplasia).3 Choroidal lesions with three or
more of these features were diagnosed as choroidal
melanoma. Asymptomatic choroidal lesions with
minimal elevation (height ,2 mm), high echogenicity,
and overlying RPE changes but no subretinal or
orange pigment were diagnosed as choroidal nevi.
Total RNA Extraction
Extraction of total RNA from serum was per-
formed following the manufacturer’s protocol using
miRNeasy Serum/Plasma Kits (QIAGEN, Hilden,
Germany) as previously described.15 A synthetic
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miRNA mimic (miRNeasy Serum/Plasma Spike-In
Control: C. elegans miR-39 miRNA mimic, Cat No
219610; QIAGEN) was spiked into each sample to
allow for normalization of expression data.
MicroRNA Panel Selection
The MELmiR-17 panel described previously10,16
was selected for analysis because all members of this
panel were found to be expressed in UM cell lines (see
Results).
Reverse Transcription, Preamplification,
Taqman Assays, and Fluidigm Real-Time PCR
A custom Taqman assay combined with a sensitive
method of detection (Fluidigm; HD Biomark, South
San Francisco, CA) was used as described.10,15 Briefly,
a custom reverse transcription (RT) primer pool
consisting of equal amounts of miRNA-specific RT
primers contained within each TaqMan Assay (Life
Technologies, Carlsbad, CA); miR-16 (000391), miR-
145-5p (002278), miR-146a-5p (000468), miR-204-5p
(000508), miR-211-5p (000514), miR-363-3p (001271),
miR-506-3p (001050), miR-508-3p (001052), miR-508-
5p (002092), miR-509-3p (002236), miR-509-5p
(002235), miR-513b (002757), miR-513c-5p (002756),
miR-514a-3p (001147), miR-4487 (462492_mat), miR-
4706 (464518_mat), and miR-4731-5p (464084_mat)
along with cel-miR-39 (000200; serum spiked-in
control) plus an additional pool of the corresponding
TaqMan MicroRNA Assay (Pre-Amp Primer Pool)
were used to preamplify the RT reaction.
qRT-PCR Analysis
Expression of the MELmiR-17 panel was assayed
in each sample with four technical replicate Taqman
assays. Real-time expression data were extracted and
analyzed as previously described.15
Statistical Methods
GraphPad Prism version 8.0.0 for Windows (San
Diego, CA) was used for all statistical analysis. Each
miRNA was assessed for expression variance using a
one-way ANOVA or Kruskal-Wallis test. Next, the
miRNA that were deemed significant (P  0.05) were
corrected for multiple comparisons using a two-stage,
linear, step-up procedure of Benjamini, Krieger, and
Table 1. Descriptive Statistics of All Serum Cohorts Used Within the Study
Prognostic Factors
Terrace Eye
Centre, n (%)
Lions Eye Institute
and Royal Perth
Hospital, n (%)
Combined
Cohorts, n (%)
Totals 43 (100) 22 (100) 65 (100)
Sex
Male 17 (40) 14 (64) 31 (48)
Female 26 (60) 8 (36) 34 (52)
Age at blood draw
20–30 2 (5) 0 (0) 2 (3)
31–40 1 (2) 0 (0) 1 (2)
41–50 5 (12) 3 (14) 8 (12)
51–60 8 (19) 11 (50) 19 (29)
61þ 27 (63) 8 (36) 35 (54)
Status at blood draw
Uveal naevus 10 (23) 0 (0) 10 (15)
Localized 31 (72) 19 (86) 50 (77)
Metastatic 2 (5) 3 (14) 5 (8)
Status at last follow-up
Alive NSR 28 (65) 13 (59) 41 (63)
Alive status unknown 6 (14) 0 (0) 6 (9)
Alive with melanoma 3 (7) 7 (32) 10 (15)
Death from melanoma 5 (12) 2 (9) 7 (11)
Unknown 1 (2) 0 (0) 1 (2)
NSR, no sign of recurrence.
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Yekutieli, which controls the false discovery rate
(FDR) and provides a corrected P value. Kaplan-
Meier survival curve analysis of each miRNA was
also assessed across sample groups. Mann-Whitney U
test was performed for pair-wise comparisons of
recurrence versus no recurrence. Predictive ability of
each miRNA was evaluated using receiver operating
characteristic (ROC curve) and area under the curve
(AUC) or AUROC (GraphPad Prism 8).
Diagnostic Score Assignment
AUC scores of 0.70 or more were deemed to be
diagnostically useful.17 The data presented in the
Figure indicated increased expression (i.e., lower
median-normalized Ct value) was associated with
disease progression. The miRNAs that had an AUC
of 0.70 or more when nevi were compared with
localized UM were interrogated further to classify the
median-normalized Ct values as ‘high’ or ‘low’
expression (interpretation of the median normalized
Ct expression values used to determine ROC curves
were evaluated using an arbitrary cut point of 85%
sensitivity). If the expression value in each sample
reached or exceeded this value then it was counted as
positive for UM (independent of disease status). This
method of determining positivity was performed for
each of the six miRNAs. For each sample, the sum of
all positive values ranged from 1 to 6. This sum is the
diagnostic score for that individual sample.
Diagnostic Score Evaluation
The diagnostic scores were evaluated using a 23 2
confusion matrix method and the following formula:
positive predictive value (PPV) or precision ¼ true
positive (TP)/(TP þ false positive [FP]); negative
predictive value (NPV) ¼ true negative (TN)/(false
negative [FN] þ TN); sensitivity ¼ TP/(TP þ FN);
specificity ¼ TN/(FP þ TN) false-positive rate ¼ 1 –
specificity; false-negative rate ¼ 1 – sensitivity;
likelihood ratio positive ¼ sensitivity/1-specificity;
likelihood ratio negative ¼ 1-sensitivity/specificity;
diagnostic odds ratio (DOR)¼ (TP/FN)/(FP/TN).
Results
A ‘Melanoma-Related’ miRNA Panel is
Expressed in Both Cutaneous and Uveal
Melanoma
Prior to evaluating the MELmiR-17 panel in
patient serum, we first confirmed that the miRNAs
were expressed in UM cell lines (n¼ 6). Importantly,
all members of this panel were found to be expressed
in at least one of the cell lines (92.1, MEL202,
MEL270, MEL285, MEL290, OMM1) previously
described and assessed via a miRNA microarray16
(see Supplementary Table S116). In our prior study,
miR-211 was the top-ranked miRNA (277-fold
average higher expression in 71% or n¼ 39/55) when
cutaneous melanomas were compared with other solid
cancer types (e.g., breast, prostate, colorectal, etc.).16
Consistent with the reported high expression in
cutaneous melanoma, miR-211 was present in 5/6
(83%) UM cell lines, and was highly expressed.16
A Panel of Six miRNAs Identifies Localized
and Metastatic Uveal Melanoma With High
Sensitivity and Specificity in Patient Sera
Expression of the MELmiR-17 panel was mea-
sured in serum samples from two independent,
prospectively collected patient cohorts (Table 1).
Study participants had a single blood drawn at
presentation with clinical signs of choroidal nevi (n
¼ 10), localized UM (n ¼ 50), or metastatic UM (n ¼
5). In miRNA derived from the patient serum, 11 of
17 miRNAs had detectable expression in all specimen
types (Fig. and Supplementary Fig. S1). No expres-
sion was detected for miR-506-3p, miR-508-3p, miR-
508-5p, miR-513b, miR-513c, or miR-514a. Of 11
detected miRNAs, six (miR-16, miR-145, miR-146a,
miR-204, miR-211, and miR-363-3p) showed signif-
icant differences (ANOVA; P , 0.05) across the
cohort. Variation in levels of the remaining five
expressed miRNAs (miR-509-3p, miR-509-5p, miR-
4487, miR-4706, and miR-4731) did not reach
significance (ANOVA; P . 0.05) across the sample
types in this study and were thus not explored further.
Interestingly, all five of these ‘‘nonsignificant’’ miR-
NAs were highly significant in our prior study
investigating cutaneous melanoma,10 which suggests
that these are more relevant in cutaneous than UM.
The miRNAs that reached or exceeded the
significance threshold (P , 0.05) were next assessed
using a multiple comparison analysis. The Figure and
Table 2 provide a summary of the multiple compar-
isons (uveal nevi versus patients with localized UM,
nevi versus metastatic UM, and localized versus
metastatic UM) and associated corrected P values
(P[cor]). All six of the significant miRNAs by
ANOVA remained significant (P[cor] ¼ 0.0462 
P[cor] , 0.0001) when uveal nevi were compared with
localized UM, with miR-16 and miR-145 being highly
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Figure. Box and Whisker plots (minimum to maximum) collate all data points represented in Table 2 for the six-miRNA panel that were
significantly different (ANOVA P , 0.05) across the cohorts of uveal nevi, localized UM, and metastatic UM. The associated corrected P
values from Table 2 are illustrated here. These data indicate the circulating levels of members of the miRNA panel increase significantly
with disease progression.
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significantly different (P[cor] , 0.0001). Next, all
ANOVA significant miRNAs (except miR-204) again
showed significance (P[cor] ¼ 0.0221  P[cor] ,
0.0001) when uveal nevi were compared with meta-
static UM, with miR-211 being highly significant
(P[cor] , 0.0001). Notably, when localized UM was
compared with metastatic UM, miR-211 was the only
member of the panel to reach significance (P[cor] ¼
0.0016) (Fig. and Table 2).
In comparisons presented in the Figure, miRNA
expression levels significantly increase with tumor
progression (uveal nevi versus localized UM), which
indicate these may be diagnostically useful in initial
diagnosis and to monitor disease progression using
serial blood draws. To determine the discriminatory
power of each of the six miRNAs, AUROC analysis
was next performed for uveal nevi versus localized
UM (Table 2 and Supplementary Fig. S2) and nevi
Table 2. Table Provides a Summary of the One-Way ANOVA (Kruskal-Wallis test) Performed to Determine
Which miRNA Showed Significant (P , 0.05) Variance Across the Cohorts
Comparison Test miR-16 miR-145 miR-146a
All cohorts (naevi,
localized, metastatic
Kruskal-Wallis test ,0.0001 ,0.0001 0.0001
Naevi (n ¼ 10) vs.
localized (n ¼ 50)
Benjamini, Krieger, and Yekutieli
method (False Discovery Rate
corrected P value)
,0.0001 ,0.0001 0.0003
AUROC score 0.92 (0.85, 0.99) 0.91 (0.84, 0.99) 0.88 (0.79, 0.98)
Naevi (n ¼ 10) vs.
metastatic (n ¼ 5)
Benjamini, Krieger, and Yekutieli
method (False Discovery Rate
corrected P value)
0.0077 0.0117 0.0019
AUROC score 0.88 (0.65, 1.0) 0.88 (0.65, 1.0) 0.86 (0.63, 1.0)
Localized (n ¼ 50) vs.
metastatic (n ¼ 5)
Benjamini, Krieger, and Yekutieli
method (False Discovery Rate
corrected P value)
0.9353 0.9514 0.3587
AUROC score nd nd nd
ns, nonsignificant or P . 0.05; nd, not defined.
Multiple testing was performed to correct for false discovery rate (Benjamini, Krieger, and Yekutieli Method, corrected P
values). AUROC analyses were performed in each cohort comparison for the 6 significant miRNAs. AUC scores with
confidence intervals are shown. Brackets represent the 95%CI.
Table 2. Extended
Comparison Test miR-204 miR-211 miR-363-3p
All cohorts (naevi,
localized, metastatic
Kruskal-Wallis test 0.0055 0.0003 0.0003
Naevi (n ¼ 10) vs.
localized (n ¼ 50)
Benjamini, Krieger, and Yekutieli
method (False Discovery Rate
corrected P value)
0.0032 0.0462 0.0003
AUROC score 0.81 (0.70, 0.93) 0.71 (0.55, 0.88) 0.86 (0.75, 0.96)
Naevi (n ¼ 10) vs.
metastatic (n ¼ 5)
Benjamini, Krieger, and Yekutieli
method (False Discovery Rate
corrected P value)
0.4009 ,0.0001 0.0221
AUROC score 0.52 (0.12, 0.92) 1.0 (1.0, 1.0) 0.92 (0.76, 1.0)
Localized (n ¼ 50) vs.
metastatic (n ¼ 5)
Benjamini, Krieger, and Yekutieli
method (False Discovery Rate
corrected P value)
0.2329 0.0016 0.9820
AUROC score nd 0.96 (0.90, 1.0) nd
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versus metastatic UM (Table 2 and Supplementary
Fig. S3). All miRNAs could be considered diagnos-
tically useful for identifying malignancy, with AUC
scores ranging from 0.7 to 1.0. Importantly, miR-211
was able to accurately distinguish metastatic disease
from localized UM (P , 0.0001; AUC ¼ 0.96)
(Supplementary Fig. S4).
The sensitivity and specificity of the miRNA panel
was then assessed by assigning a diagnostic score to
the data. The expression values graphed in the Figure
were used to observe the direction of the data (i.e.,
higher expression in localized UM versus uveal nevi).
The cut-points in the AUROC datasets (not shown)
were identified which allowed the expression values to
be categorized as positive or negative for UM (see
Materials and Methods). Upon applying the derived
diagnostic score, the miRNA panel can then be
evaluated as a group. Based upon these discovery
data, the miRNA panel had the ability to identify UM
(localized and metastatic), when four or more
miRNAs (93% sensitivity and 100% specificity)
reached or exceeded their cut-point (Table 3). The
FP and FN rate was used to determine the lowest
diagnostic score possible for the miRNA panel while
still maintaining very high sensitivity and specificity.
For example, when a specimen had a score of 3 or
more, the sensitivity was high (93%) but specificity
was unacceptably low (60%). Likewise, if 5 were
included, this achieved 100% specificity but reduced
the sensitivity to 82%. Following on from this
interpretation, a diagnostic score can then be applied
to each sample, which ranges from 0 to 3 (lower
likelihood of UM) and 4 to 6 (higher likelihood of
UM).
Recurrence and Overall Survival
In the Queensland Ocular Oncology Service cohort
(Table 1) with 4- to 5-year follow-up data available,
one of 10 pigmented choroidal lesion demonstrated
growth. In study participants presenting with local-
ized UM, five of 31 (16%) developed liver metastases,
with two of five confirmed deaths from UM. We next
assessed the Lions Eye Institute and Royal Perth
Hospital cohort with up to 4-year follow-up infor-
mation available. In participants presenting with
localized UM, three of 19 (16%) had a localized
recurrence, with one participant progressing further
to metastatic disease. Overall, five of 19 (26%)
participants from this cohort developed liver (4/5,
80%) or lung (1/5, 20%) metastases with two of five
confirmed deaths from UM.
The miRNA panel was next analyzed for associ-
ation with recurrence (local or metastatic) and overall
survival (OS). With a single blood draw, no statisti-
cally significant association with recurrence or time to
recurrence (Mann-Whitney U test and Kaplan Meier
survival curve analysis respectively; data not shown)
was evident in either cohort. Next the six-miRNA
panel was assessed for OS using optimal cut points in
the dataset to determine ‘‘high’’ and ‘‘low’’ expression.
Table 3. Results of the Diagnostic Test Evaluations Generated When Uveal Nevi is Compared With Localized
and/or Metastatic Melanoma
miRNA Panel
Uveal Naevi vs. Localized
or Metastatic Melanoma
Uveal Naevi vs. Localised
or Metastatic Melanoma
Uveal Naevi vs. Localised
or Metastatic Melanoma
Diagnostic score 3 4 5
Sensitivity, % 93 93 82
Specificity, % 60 100 100
False-positive rate, % 40 0 0
False-negative rate, % 7 7 18
PPV, % 93 100 100
NPV, % 60 76 50
Likelihood ratio positive 2 ~20 ~18
Likelihood ratio negative 0.13 0.07 0.19
DOR 19 ~240 ~93
The associated results are presented for the diagnostic scores of 3, 4, and 5 which is the total number of miRNAs
(of 6) expressed per sample that reach or exceed the cut point of 85% sensitivity (see Materials and Methods). The bolded
results represent the diagnostic score (4) that gave the highest sensitivity (93%) and specificity (100%). The likelihood
ratios (positive) and diagnostic odds ratios shown as approximate were calculated by adding 0.5 to the 23 2 confusion
matrix as the number of false-positives was zero.
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Interestingly, low-circulating miR-204 expression was
found to be significantly (Log rank, P ¼ 0.014)
associated with poor overall survival as compared
with high-circulating expression levels (Supplementa-
ry Fig. S5). All other miRNA showed nonsignificant
associations with OS, however high miR-211 expres-
sion did have a nonsignificant trend toward poor OS
(Supplementary Fig. S5).
A paired blood draw was available for one
individual who presented with localized UM. With
blood draws approximately 1 year apart, expression
levels were increased at follow-up for miR-211 but not
for any of the other miRNAs (data not shown).
Follow-up information from this individual revealed a
localized recurrence 8 months later, which metastasized
approximately 1 year postrecurrence. It is not possible
to draw a firm conclusion with only one paired sample;
however, these observational data are consistent with
the overall cohort analysis, whereby miR-211 was the
sole miRNA to identify metastatic UM.
Discussion
A recent review of clinical studies validated the
high degree of diagnostic accuracy of a multistep
clinical diagnostic guideline for choroidal nevi.18 The
suggested guideline lists risk factors for transforma-
tion as lesion thickness (.2 mm), subretinal fluid,
symptoms (e.g., decreased vision), orange lipofuscin,
tumor margin within 3 mm of the optic disc,
ultrasonographic hollowness, and lack of halo. The
presence of three risk factors confers a 50% chance of
malignant transformation. Notably, a lesion present-
ing with more than 2-mm thickness, symptoms, and
location near the disc has a 69% risk of growth.3 Once
diagnosed with a choroidal nevus with ‘‘high-risk’’
features, or following treatment of noninvasive UM,
patients and treating clinicians alike are left with some
uncertainty over the malignant propensity of these
lesions—as such there is a great need for a biomarker
to confirm initial diagnosis as well as to detect early
signs of malignant change and metastatic progression.
Herein, we describe a panel of six circulating
miRNAs that may fulfill this clinical need. This panel
offers a high degree of precision to the diagnosis of
UM, achieving 93% sensitivity and 100% specificity.
The clinical utility of this panel is evident at the nevus
stage of diagnosis, with circulating miRNA expression
levels accurately distinguishing benign lesions from UM
(Fig. and Table 2). Following subsequent validation
studies in larger longitudinal study cohorts, this panel
could be used as a companion diagnostic tool to assist
in clinical decision making. Such as, at initial presen-
tation, to inform a decision between close observation
and monitoring a suspicious borderline lesion, or
treatment to achieve early local tumor control.
Furthermore, this panel may be well-suited for a
minimally invasive tool to serially monitor patients
initially presenting with benign lesions to identify signs
of progression at subsequent follow-up visits.
Since commencement of this study, there have
been a small number of studies investigating the
utility of circulating miRNAs, as well as a soluble
oncoprotein (c-Met), for UM detection.12–14,19 A
common miRNA to all studies is miR-146a, which
was found to be upregulated in UM patient serum/
plasma as well as archival tissues.12–14 In our study,
we too confirmed that miR-146a was increased in the
serum of localized (P[cor] ¼ 0.0003) and metastatic
(P[cor] ¼ 0.0019) UM patients as compared with
individuals with uveal nevi. In these prior studies,
miR-146a was proposed to be circulating marker of
UM, and our data support the use of miR-146a as a
member of a panel to increase diagnostic accuracy.
A limitation of this study is the small sample size of
participants with metastatic UM or choroidal nevi, a
larger cohort, which would enable thorough investi-
gation of the clinical risk features that have been
identified.3 In addition, without serial blood draws
(except for one individual), this panel was unable to
predict or detect recurrence. Low miR-204 expression
did however have a significant association with poor
prognosis (Supplementary Fig. S5).
Conclusion
In both cutaneous and uveal melanoma, early
detection of primary lesions offers the best hope to
prevent progression to metastatic disease. This is a
difficult task in the case of UM as uveal nevi may
remain stable for the duration of a patient’s life but
require regular monitoring by a specialized ocular
oncologist. Currently, there are no biomarkers
available for use in clinical practice that offer a
degree of diagnostic certainty. The six-miRNA panel
described herein offers promise in identifying early
signs of malignant transformation and progression
detection. However, further investigation and valida-
tion in larger prospective cohorts is warranted.
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